In two large clinical trials, in which semaglutide was used to treat different patient groups for which NAFLD is a known comorbidity, there were clear dose‐dependent reductions in both ALT and hsCRP. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.